Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Blog Article

Abstract Background Patients with Oval Dining Table multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population.We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.Results Rates adverse reactions were low and consistent with those documented in vaccine trials.Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.Conclusions Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and Snacks leads to high rates of seroconversion in patients with MM.

These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.